Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2 and Beyond: Mutational Study of JAK2V617 in Myeloproliferative Disorders and Haematological Malignancies in Kashmiri population.

Asian Pacific journal of cancer prevention : APJCP - 1 Dec 2019

Syeed Nidda

Abstract excerpt

BACKGROUND: Janus Tyrosine Kinase-2 (JAK2 V617F), a novel point mutation affecting the MPD'S is a somatic gain-of-function mutation. It alters a highly conserved amino acid valine in the negative regulatory JH2 domain to phenylalanine predicted to dysregulate kinase activity. AIM: To evaluate the prevalence and clinical significance of JAK2 V617F mutation in various MPD's as well as in hematological malignancies....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Substitution
Share to Bone Marrow Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hematologic Neoplasms

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Point Mutation

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 31870101
DOI: 10.31557/APJCP.2019.20.12.3611
PMCID: PMC7173381

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2 and Beyond: Mutational Study of JAK2V617 in Myeloproliferative Disorders and Haematological Malignancies in Kashmiri population.PMID 31870101Read ↗

Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders.Semantic proximity Read ↗

[Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].Semantic proximity Read ↗

The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.Semantic proximity Read ↗

The JAK2 mutation.Semantic proximity Read ↗

Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory.Semantic proximity Read ↗

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.Semantic proximity Read ↗

New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms.Semantic proximity Read ↗

JAK and MPL mutations in myeloid malignancies.Semantic proximity Read ↗

JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?Semantic proximity Read ↗

JAK2 in myeloproliferative disorders is not just another kinase.Semantic proximity Read ↗

Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders.Semantic proximity Read ↗

Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.